Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH -1.24%88 EV-to-OCF is 34.54 as of Jul. 30, 2026, which is 11% below its 10-year median of 38.93. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.72 (Fairly Valued). The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 87.21% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's EV-to-OCF or its related term are showing as below:
ASX:FPH'
s EV-to-OCF Range Over the Past 10 Years
Min: 22.22 Med: 38.93 Max: 67.88
Current: 34.43
During the past 13 years, the highest EV-to-OCF of Fisher & Paykel Healthcare was 67.88. The lowest was 22.22. And the median was 38.93.
ASX:FPH's EV-to-OCF is ranked worse than 87.21% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.865
vs ASX:FPH: 34.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fisher & Paykel Healthcare's PE Ratio (TTM) for today is calculated as:
Fisher & Paykel Healthcare's share price for today is A$34.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.682.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fisher & Paykel Healthcare EV-to-OCF Related Terms
Fisher & Paykel Healthcare EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's EV-to-OCF falls into.
Fisher & Paykel Healthcare's current Enterprise Value is A$19,586 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$567 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a EV-to-OCF of 34.54 as of Jul. 30, 2026. This is 11% below median its historical median of 38.93. Over the past decade, Fisher & Paykel Healthcare's EV-to-OCF has ranged from 22.22 to 67.88. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #743 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 87.2%.
Is Fisher & Paykel Healthcare's EV-to-OCF too high?
Fisher & Paykel Healthcare's current EV-to-OCF of 34.54 is 11% below median its 10-year median of 38.93. Over the past 10 years, this metric has ranged from a low of 22.22 to a high of 67.88. The Medical Devices & Instruments industry median EV-to-OCF is 7.87. Fisher & Paykel Healthcare's value of 34.54 is 339.2% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #743 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #743 out of 852 companies for EV-to-OCF. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median EV-to-OCF is 7.87. Fisher & Paykel Healthcare's value of 34.54 is 339.2% above this benchmark. Historically, Fisher & Paykel Healthcare's own EV-to-OCF has ranged from 22.22 to 67.88 over the past decade. While the company's 10-year median is 38.93 vs. the industry median of 7.87, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.87, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EV-to-OCF of 34.54 is 339.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EV-to-OCF is 34.54, which is 11% below median its own 10-year median of 38.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.72, compared to a current price of A$34.24 — trading 6.8% below its estimated fair value. The current EV-to-OCF is 34.54, which is 11% below median its 10-year median of 38.93 and 339.2% above the Medical Devices & Instruments industry median of 7.87. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current EV-to-OCF is 34.54 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$34.24 is trading 6.8% below its estimated GF Value™ of A$36.72.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
EV-to-OCF: 34.54 (11% below median its 10-year median of 38.93)
GF Value™: A$36.72 vs. price of A$34.24 (6.8% below fair value)
Industry Position: 339.2% above the Medical Devices & Instruments median (#743 of 852)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
